The correlation of GluR3B antibody with T lymphocyte subsets and inflammatory factors and their role in the progression of epilepsy.
Epilepsy
GluR3B antibody
Immunotherapy
Lymphocyte subsets
Proinflammatory cytokines
Structural equation modeling
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
22
06
2024
accepted:
23
09
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
1
10
2024
Statut:
epublish
Résumé
To investigate changes in proportions of peripheral blood lymphocyte subsets, the correlation between the lymphocyte subsets and cytokine levels in patients with GluR3B antibody-positive epilepsy, analyze the role of GluR3B antibodies and cytokines in the progression of epilepsy. In addition, the immunotherapeutic effect in patients with GluR3B antibody-positive epilepsy will be evaluated. Patients with epilepsy hospitalized in the Department of Neurology of the affiliated Hospital of Xuzhou Medical University from December 2016 to May 2023 were recruited. GluR3B antibody levels were measured by enzyme-linked immunosorbent assay (ELISA). Lymphocyte subset proportions were determined using flow cytometry, and serum concentrations of 12 cytokines were measured using cytometric beads array. Differences in T lymphocyte subsets and inflammatory factors were analysed between GluR3B antibody positive and negative patients. Structural equation modeling (SEM) was used to analyse the role of GluR3B antibodies and inflammatory factors in drug-resistant epilepsy (DRE). Finally, the therapeutic effect of immunotherapy on epilepsy patients with GluR3B antibodies was assessed. In this study, sixty-four cases of DRE, sixty-six cases of drug-naïve epilepsy (DNE), and forty-one cases of drug-responsive epilepsy were recruited. (1) DRE patients with positive GluR3B antibody were characterized by a significant increase in the proportion of cluster of differentiation (CD)4 This study demonstrates that GluR3B antibody may influence the progression of epilepsy through altering the proportion of CD4
Identifiants
pubmed: 39350251
doi: 10.1186/s12967-024-05699-2
pii: 10.1186/s12967-024-05699-2
doi:
Substances chimiques
glutamate receptor ionotropic, AMPA 3
0
Cytokines
0
Receptors, AMPA
0
Inflammation Mediators
0
Autoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
877Subventions
Organisme : Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy
ID : KF-XY201904
Organisme : Natural Science Foundation of Jiangsu Province
ID : BK20221221
Organisme : Fundamental Research Funds for the Central Universities
ID : 2020QN84
Organisme : Xuzhou Science and Technology Program
ID : XWKYHT20210582
Informations de copyright
© 2024. The Author(s).
Références
Ding D, Zhou D, Sander JW, et al. Epilepsy in China:major progress in the past two decades. Lancet Neurol. 2021;20(4):316–26.
pubmed: 33743240
doi: 10.1016/S1474-4422(21)00023-5
Duncan JS, Sander JW, Sisodiya SM, et al. Adult Epilepsy Lancet. 2006;367(9516):1087–100.
pubmed: 16581409
Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in Autoimmune diseases of the Central Nervous System. Physiol Rev. 2017;97:839–87.
pubmed: 28298428
pmcid: 5539405
doi: 10.1152/physrev.00010.2016
Ong MS, Kohane IS, Cai T, et al. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol. 2014;71:569–74.
pubmed: 24687183
pmcid: 4324719
doi: 10.1001/jamaneurol.2014.188
Miryusifova Kh, Malikova G, Allahverdiyeva A, et al. The saffron effects on the dynamics of experimental epilepsy. Adv Biology Earth Sci. 2024;9(1):196–202.
doi: 10.62476/abes9196
Steriade C, Gillinder L, Rickett K, et al. Discerning the role of autoimmunity and autoantibodies in epilepsy: a review. JAMA Neurol. 2021;78(11):1383–90.
pubmed: 34515743
doi: 10.1001/jamaneurol.2021.3113
Dubey D, Alqallaf A, Hays R, et al. Neurological autoantibody prevalence in epilepsy of unknown etiology. JAMA Neurol. 2017;74(4):397–402.
pubmed: 28166327
doi: 10.1001/jamaneurol.2016.5429
Elisak M, Krysl D, Hanzalova J, et al. The prevalence of neural antibodies in temporal lobe epilepsy and the clinical characteristics of seropositive patients. Seizure. 2018;63:1–6.
pubmed: 30391660
doi: 10.1016/j.seizure.2018.09.009
Chen S, Xu D, Fan L, et al. Roles of N-Methyl-D-Aspartate receptors (NMDARs) in Epilepsy. Front Mol Neurosci. 2022;14:797253.
pubmed: 35069111
pmcid: 8780133
doi: 10.3389/fnmol.2021.797253
Fedele L, Newcombe J, Topf M, et al. Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties. Nat Commun. 2018;9(1):957.
pubmed: 29511171
pmcid: 5840332
doi: 10.1038/s41467-018-02927-4
Brändle SM, Cerina M, Weber S et al. Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABAA receptor encephalitis. P Natlacad Sci Usa. 2021;118(9).
Pişkin ŞA, Korkmaz HY, Ulusoy CA, et al. Antibody induced seizure susceptibility and impaired cognitive performance in a passive transfer rat model of autoimmune encephalitis. Front Immunol. 2023;14:1268986.
pubmed: 38035091
pmcid: 10684964
doi: 10.3389/fimmu.2023.1268986
Ramberger M, Berretta A, Tan JMM, et al. Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms. Brain. 2020;143(6):1731–45.
pubmed: 32437528
pmcid: 7296845
doi: 10.1093/brain/awaa104
Twyman RE, Gahring LC, Spiess J, et al. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site. Neuron. 1995;14:755–62.
pubmed: 7718238
doi: 10.1016/0896-6273(95)90219-8
Ganor Y, Gottlieb M, Eilam R, et al. Immunization with the glutamate receptor -derived peptide GluR3B induces neuronal death and reactive gliosis, but confers partial protection from pentylenetetrazole-induced seizures. Exp Neurol. 2005;195:92–102.
pubmed: 15907325
doi: 10.1016/j.expneurol.2005.04.002
Levite M, Fleidervish IA, Schwarz A, et al. Autoantibodies to the glutamate receptor kill neurons via activation of the receptor ion channel. J Autoimmun. 1999;13:61–72.
pubmed: 10441169
doi: 10.1006/jaut.1999.0301
Levite M, Hermelin A. Autoimmunity to the glutamate receptor in mice–a model for Rasmussen’s encephalitis? J Autoimmun. 1999;13:73–82.
pubmed: 10441170
doi: 10.1006/jaut.1999.0297
Whitney KD, McNamara JO. GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. J Neurosci. 2000;20(19):7307–16.
pubmed: 11007888
pmcid: 6772766
doi: 10.1523/JNEUROSCI.20-19-07307.2000
Mantegazza R, Bernasconi P, Baggi F, et al. Antibodies against GluR3 peptides are not specific for Rasmussen’s encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol. 2002;131:179–85.
pubmed: 12458050
doi: 10.1016/S0165-5728(02)00261-8
Wiendl H, Bien CG, Bernasconi P, et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen’s encephalitis. Neurology. 2001;57:1511–4.
pubmed: 11673604
doi: 10.1212/WNL.57.8.1511
Goldberg-Stern H, Ganor Y, Cohen R, et al. Glutamate receptor antibodies directed against AMPA receptors subunit 3 peptide B (GluR3B) associate with some cognitive/psychiatric/behavioral abnormalities in epilepsy patients. Psychoneuroendocrinology. 2014;40:221–31.
pubmed: 24485494
doi: 10.1016/j.psyneuen.2013.11.007
Ganor Y, Goldberg-Stern H, Cohen R, et al. Glutamate receptor antibodies directed against AMPA receptors subunit 3 peptide B (GluR3B) can be produced in DBA/2J mice, lower seizure threshold and induce abnormal behavior. Psychoneuroendocrinology. 2014;42:106–17.
pubmed: 24636507
doi: 10.1016/j.psyneuen.2014.01.005
Antozzi C, Granata T, Aurisano N, et al. Long-term selective IgG immuno -adsorption improves Rasmussen’s encephalitis. Neurology. 1998;51:302–5.
pubmed: 9674829
doi: 10.1212/WNL.51.1.302
Granata T, Fusco L, Gobbi G, et al. Experience with immunomodulatory treatments in Rasmussen’s encephalitis. Neurology. 2003;61:1807–10.
pubmed: 14694056
doi: 10.1212/01.WNL.0000099074.04539.E0
Rogers SW, Andrews PI, Gahring LC, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen’s encephalitis. Science. 1994;265:648–51.
pubmed: 8036512
doi: 10.1126/science.8036512
Lai QW, Li QY, Li XY, et al. GluR3B antibody was a Biomarker for Drug-Resistant Epilepsy in patients with focal to bilateral Tonic-Clonic seizures. Front Immunol. 2022;13:838389.
pubmed: 35464426
pmcid: 9018978
doi: 10.3389/fimmu.2022.838389
Bauer S, Köller M, Cepok S, et al. NK and CD4 + T cell changes in blood after seizures in temporal lobe epilepsy. Exp Neurol. 2008;211(2):370–7.
pubmed: 18387608
doi: 10.1016/j.expneurol.2008.01.017
Helmstaedter C, Hansen N, Leelaarporn P, et al. Specific B- and T-cell populations are associated with cognition in patients with epilepsy and antibody positive and negative suspected limbic encephalitis. J Neurol. 2020;268(2):455–66.
pubmed: 32816110
pmcid: 7880943
doi: 10.1007/s00415-020-10158-1
Sanli E, Sirin NG, Kucukali CI, et al. Peripheral blood regulatory B and T cells are decreased in patients with focal epilepsy. J Neuroimmunol. 2024;387:578287.
pubmed: 38241950
doi: 10.1016/j.jneuroim.2024.578287
Levite M, Zelig D, Friedman A, et al. Dual-targeted Autoimmune Sword in Fatal Epilepsy: patient’s glutamate receptor AMPA GluR3B peptide Au toimmune antibodies bind, induce reactive oxygen species (ROS) in, and kill both human neural cells and T cells. J Autoimmun. 2020;112:102462.
pubmed: 32561150
doi: 10.1016/j.jaut.2020.102462
Tekgul H, Polat M, Kitis O, et al. T-cell subsets and interleukin-6 response in Rasmussen’s encephalitis. Pediatr Neurol. 2005;33:39–45.
pubmed: 15876522
doi: 10.1016/j.pediatrneurol.2005.01.007
Langenbruch L, Ble L, Schulte-Mecklenbeck A, et al. Blood and cerebrospinal fluid immune cell profiles in patients with temporal lobe epilepsy of different etiologies. Epilepsia. 2020;61:e153–8.
pubmed: 32893887
doi: 10.1111/epi.16688
Ouédraogo O, Rébillard RM, Jamann H, et al. Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drug-resistant epilepsy. Epilepsia. 2021;62:176–89.
pubmed: 33140401
doi: 10.1111/epi.16742
Pitsch J, van Loo KMJ, Gallus M, et al. CD8 + T-Lymphocyte-driven limbic encephalitis results in temporal lobe Epilepsy. Ann Neurol. 2021;89:666–85.
pubmed: 33368582
doi: 10.1002/ana.26000
Basnyat P, Peltola M, Raitanen J, et al. Elevated IL-6 plasma levels are associated with GAD antibodies-associated autoimmune epilepsy. Front Cell Neurosci. 2023;17:1129907.
pubmed: 37025699
pmcid: 10070787
doi: 10.3389/fncel.2023.1129907
Andrews PI, Dichter MA, Berkovic SF, et al. Plasmapheresis in Rasmussen’s encephalitis. Neurology. 1996;46:242–6.
pubmed: 8559385
doi: 10.1212/WNL.46.1.242
Andrews PI, McNamara JO, Lewis DV. Clinical and electroencephalographic correlates in Rasmussen’s encephalitis. Epilepsia. 1997;38:189–94.
pubmed: 9048671
doi: 10.1111/j.1528-1157.1997.tb01096.x
Leach JP, Chadwick DW, Miles JB, et al. Improvement in adult-onset Rasmussen’s encephalitis with long-term immunomodulatory therapy. Neurology. 1999;52(4):738–42.
pubmed: 10078719
doi: 10.1212/WNL.52.4.738
Feichtinger M, Wiendl H, Korner E, et al. No effect of immunomodulatory therapy in focal epilepsy with positive glutamate receptor type 3-antibodies. Seizure. 2006;15(5):350–4.
pubmed: 16621617
doi: 10.1016/j.seizure.2006.03.002
Steriade C, Britton J, Dale RC, et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: conceptual definitions. Epilepsia. 2020;61(7):1341–51.
pubmed: 32544279
doi: 10.1111/epi.16571
Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League against Epilepsy: position paper of the ILAE Commission for classification and terminology. Epilepsia. 2017;58(4):522–30.
pubmed: 28276060
doi: 10.1111/epi.13670
Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on therapeutic strategies. Epilepsia. 2010;51:1069–77.
pubmed: 19889013
doi: 10.1111/j.1528-1167.2009.02397.x
Larochelle C, Cayrol R, Kebir H, et al. Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system. Brain. 2012;135:2906–24.
pubmed: 22975388
doi: 10.1093/brain/aws212
Larochelle C, Uphaus T, Broux B, et al. EGFL7 reduces CNS inflammation in mouse. Nat Commun. 2018;9:819.
pubmed: 29483510
pmcid: 5827652
doi: 10.1038/s41467-018-03186-z
Bain KA, McDonald E, Moffat F, et al. Alopecia Areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. Br J Dermatol. 2020;182:130–7.
pubmed: 30980732
Rosa DV, Rezende VB, Costa BS, et al. Circulating CD4 and CD8 T cells expressing pro-inflammatory cytokines in a cohort of mesial temporal lobe epilepsy patients with hippocampal sclerosis. Epilepsy Res. 2015;120:1–6.
pubmed: 26709876
doi: 10.1016/j.eplepsyres.2015.11.011
Sanli E, Akbayir E, Kuçukali CI, et al. Adaptive immunity cells are differentially distributed in the peripheral blood of glycine receptor antibody-positive patients with focal epilepsy of unknown cause. Epilepsy Res. 2021;170:106542.
pubmed: 33387801
doi: 10.1016/j.eplepsyres.2020.106542
Luchtman DW, Ellwardt E, Larochelle C, et al. IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: current and future developments. Cytokine Growth Factor Rev. 2014;25:403–13.
pubmed: 25153998
doi: 10.1016/j.cytogfr.2014.07.013
Vogelaar CF, Mandal S, Lerch S et al. Fast direct neuronal signaling via the IL-4 receptor as therapeutic target in neuroinflammation. Sci Transl Med. 2018;10.
Hara A, Chihara N, Akatani R, et al. Circulating plasmablasts and follicular helper T-cell subsets are associated with antibody-positive autoimmune epilepsy. Front Immunol. 2022;13:1048428.
pubmed: 36569937
pmcid: 9773883
doi: 10.3389/fimmu.2022.1048428
Gillinder L, McCombe P, Powell T, et al. Cytokines as a marker of central nervous system autoantibody associated epilepsy. Epilepsy Res. 2021;176:106708.
pubmed: 34271300
doi: 10.1016/j.eplepsyres.2021.106708
Qiao S, Sun QY, Zhou P, et al. Increased formation of neutrophil extracellular traps in patients with anti-N-methyl-d-aspartate receptor encephalitis. Front Immunol. 2022;13:1046778.
pubmed: 36569875
pmcid: 9780054
doi: 10.3389/fimmu.2022.1046778
Liba Z, Kayserova J, Elisak M, et al. Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid. J Neuroinflammation. 2016;13:55.
pubmed: 26941012
pmcid: 4776396
doi: 10.1186/s12974-016-0507-9
Vezzani A, Friedman A, Dingledine RJ. The role of inflammation in epileptogenesis. Neuropharmacology. 2013;69:16–24.
pubmed: 22521336
doi: 10.1016/j.neuropharm.2012.04.004
Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci. 2011;108:3701–6.
pubmed: 21321193
pmcid: 3048150
doi: 10.1073/pnas.1017385108
Mäkelä KM, Hietaharju A, Brander A, et al. Clinical management of Epilepsy with glutamic acid decarboxylase antibody positivity: the interplay between Immunotherapy and anti-epileptic drugs. Front Neurol. 2018;9:579.
pubmed: 30057567
pmcid: 6053535
doi: 10.3389/fneur.2018.00579